Maintenance trastuzumab in the setting of second-line treatment in HER2 overexpressing metastatic gastric and gastroesophageal junction adenocarcinoma: Experience of our centre

被引：0
|
作者：
Lopez Lopez, F. [1 ]
Yarza Barrio, R. [1 ]
Espinosa Olarte, P. [1 ]
Gomez-Martin, C. [1 ]
机构：
[1] Hosp Univ 12 Octubre, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.432
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-350
引用
收藏
页码：S203 / S204
页数：2
相关论文
共 50 条
  • [1] Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
    Pericay, Carles
    Rivera, Fernando
    Gomez-Martin, Carlos
    Nunez, Inmaculada
    Cassinello, Alejo
    Rodrigo Imedio, Esteban
    CANCER MEDICINE, 2016, 5 (12): : 3464 - 3474
  • [2] Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
    Schlintl, Verena
    Huemer, Florian
    Greil, Richard
    Weiss, Lukas
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (02) : 906 - 909
  • [3] Trastuzumab-deruxtecan in HER2 positive advanced gastric or gastroesophageal junction cancer after previous treatment with trastuzumab
    Duval, Jeanne
    Zaanan, Aziz
    BULLETIN DU CANCER, 2023, 110 (7-8) : 739 - 740
  • [4] Trastuzumab a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer
    Lordick, Florian
    FUTURE ONCOLOGY, 2011, 7 (02) : 187 - 199
  • [5] Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
    Iqbal, Muhammad Shahid
    Shaikh, Ghazia
    Chatterjee, Sanjoy
    Cocks, Helen
    Kovarik, Josef
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2014, 2014
  • [6] Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
    Von Cheong, E.
    Ho, Gwo Fuang
    CLINICAL CASE REPORTS, 2021, 9 (04): : 2264 - 2268
  • [7] Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer
    Morabito, Alessandro
    Longo, Raffaele
    Gattuso, Domenico
    Carillio, Guido
    Massaccesi, Cristian
    Mariani, Luigi
    Bonginelli, Paola
    Amici, Scolastica
    De Sio, Livia
    Fanelli, Massimo
    Torino, Francesco
    Bonsignori, Maurizio
    Gasparini, Giampietro
    ONCOLOGY REPORTS, 2006, 16 (02) : 393 - 398
  • [8] Irinotecan plus trastuzumab as a second-line treatment for HER2-positive gastric cancer
    Maeda, Osamu
    Ando, Takafumi
    Ishiguro, Kazuhiro
    Watanabe, Osamu
    Miyahara, Ryoji
    Nakamura, Masanao
    Funasaka, Kohei
    Goto, Hidemi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 224 - 225
  • [9] Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment
    Turkmen, Esma
    Erdogan, Bulent
    Kodaz, Hilmi
    Hacibekiroglu, Ilhan
    Onal, Yilmaz
    Uzunoglu, Sernaz
    Kilic, Nilufer
    Cicin, Irfan
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2016, 79 (02) : 211 - 215
  • [10] PTEN Loss Predicts Poor Response to Trastuzumab in HER2 Overexpressing Gastric or Esophageal Adenocarcinoma
    Deguchi, Yasunori
    Okabe, Hiroshi
    Oshima, Nobu
    Hisamori, Shigeo
    Sakai, Yoshiharu
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2016, 223 (04) : E47 - E47
12345